Telomir reports progress in anti-aging drug study

This post was originally published on this site

The data, stemming from studies on human cell lines, was showcased in a scientific poster titled “Telomir-1 Induces Telomere Extensions in Primary Human Cell Strains” by Danielle R. Baker, Ph.D., of Frontage Laboratories. The poster, presented last week, detailed the effects of Telomir-1 on telomere length in fetal lung fibroblasts, endothelial cells, and mesenchymal stem cells.

Chris Chapman, MD, co-founder and CEO of Telomir, expressed optimism about the potential of Telomir-1 to extend human life and improve health by reversing age-related decline. Dr. Michael Roizen, a special advisor to the company, added that while further research is required, the preliminary findings suggest the possibility of preventing diseases traditionally associated with aging.

The company is also collaborating with InSilicoTrials, utilizing AI and simulations to expedite drug development and improve the safety profile of Telomir-1. The collective aim is to develop Telomir-1 for conditions like hemochromatosis and post-chemotherapy recovery, among other age-related diseases.

Telomir’s approach aligns with the mission of the NUHS Centre for Healthy Longevity, which is dedicated to advancing research and interventions that promote longevity and delay aging.

The information in this article is based on a press release.

Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) has been capturing investor attention with its innovative approach to age-related diseases. While the scientific community is cautiously optimistic about the potential of Telomir-1, investors are looking at the financial health and stock performance of TELO with equal interest. Here are some insights based on real-time data and InvestingPro Tips for Telomir Pharmaceuticals:

The market cap of Telomir stands at $259.38 million, reflecting the company’s valuation in the eyes of the market. Despite the pre-clinical status of its drug, Telomir-1, the company’s stock has experienced a strong return over the last year, with a year-to-date price total return of 75.2%. This could be indicative of investor confidence in the company’s future.

InvestingPro Tips suggest that TELO operates with a moderate level of debt and has shown strong returns over the last month, three months, and six months, which may appeal to investors looking for growth potential. However, it’s important to note that the company has not been profitable over the last twelve months, and short term obligations exceed liquid assets, posing potential liquidity risks. Additionally, TELO is trading at a high Price / Book multiple of 119.09, which could signal that the stock is currently valued at a premium compared to its book value.

For investors seeking a deeper analysis, InvestingPro provides an additional 10 tips on Telomir Pharmaceuticals, offering a comprehensive view of the company’s financial health and stock performance. To explore these insights and more, visit https://www.investing.com/pro/TELO and use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.